论文部分内容阅读
目的探讨坦索罗辛联合吡啶斯的明治疗合并逼尿肌功能低下的前列腺增生(BPH)的有效性。方法93例BPH患者分三组:A组30例,坦索罗辛0.2mg,每日一次;B组32例,吡啶斯的明60mg,每日二次;C组31例,按A、B组方案两药联合使用。治疗4周,比较疗效。结果与治疗前比较,A、C组治疗后国际前列腺症状评分(IPSS)评分明显下降(P<0.05,P<0.01),C组最大尿流率(Qmax)明显上升(P<0.01),A组残余尿(PVR)明显下降(P<0.05),C组下降更明显(P<0.01)。结论对于合并逼尿肌功能低下的BPH,坦索罗辛与吡啶斯的明联合用药比单一用药更为有效。
Objective To investigate the efficacy of tamsulosin combined with pyridostigmine in the treatment of prostatic hyperplasia (BPH) with detrusor dysfunction. Methods Ninety-three patients with BPH were divided into three groups: group A (n = 30) and tamsulosin 0.2 mg once daily; group B (n = 32) with pyridostigmine 60 mg twice daily; group C Group plans to use two drugs in combination. Treatment for 4 weeks, more effective. Results Compared with those before treatment, the scores of IPSS in A and C groups were significantly decreased (P <0.05, P <0.01), and the Qmax in C group was significantly increased (P <0.01), and A Group residual urine (PVR) decreased significantly (P <0.05), C group decreased more significantly (P <0.01). Conclusions Tamsulosin and pyridostigmine are more effective than monotherapy in BPH with detrusor dysfunction.